WINTON GROUP Ltd Takes Position in Avanos Medical Inc (AVNS)

WINTON GROUP Ltd purchased a new position in shares of Avanos Medical Inc (NYSE:AVNS) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 161,191 shares of the company’s stock, valued at approximately $11,042,000. WINTON GROUP Ltd owned approximately 0.34% of Avanos Medical as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of AVNS. Oregon Public Employees Retirement Fund purchased a new position in shares of Avanos Medical during the 2nd quarter valued at $1,033,000. Public Employees Retirement System of Ohio purchased a new position in shares of Avanos Medical during the 2nd quarter valued at $136,000. McQueen Ball & Associates Inc. purchased a new position in shares of Avanos Medical during the 3rd quarter valued at $268,000. CENTRAL TRUST Co purchased a new position in shares of Avanos Medical during the 3rd quarter valued at $167,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Avanos Medical during the 3rd quarter valued at $704,000. 84.10% of the stock is currently owned by institutional investors and hedge funds.

NYSE AVNS opened at $50.70 on Friday. Avanos Medical Inc has a 52-week low of $43.78 and a 52-week high of $72.96. The company has a quick ratio of 2.18, a current ratio of 2.78 and a debt-to-equity ratio of 0.19. The firm has a market cap of $2.36 billion, a PE ratio of 21.22 and a beta of 1.86.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.09. Avanos Medical had a net margin of 14.26% and a return on equity of 6.59%. The company had revenue of $165.10 million during the quarter, compared to the consensus estimate of $166.57 million. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, equities analysts expect that Avanos Medical Inc will post 1.83 EPS for the current year.

AVNS has been the subject of a number of recent analyst reports. Raymond James upgraded shares of Avanos Medical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 21st. Morgan Stanley lifted their price objective on shares of Avanos Medical from $58.00 to $60.00 and gave the stock an “underweight” rating in a report on Wednesday, August 8th. Barclays began coverage on shares of Avanos Medical in a report on Monday, October 15th. They set an “equal weight” rating and a $69.00 price objective for the company. Zacks Investment Research downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a report on Friday, October 12th. Finally, KeyCorp lifted their price objective on shares of Avanos Medical from $66.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $69.25.

TRADEMARK VIOLATION NOTICE: “WINTON GROUP Ltd Takes Position in Avanos Medical Inc (AVNS)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/11/10/winton-group-ltd-takes-position-in-avanos-medical-inc-avns.html.

Avanos Medical Profile

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Further Reading: Growth Stocks

Institutional Ownership by Quarter for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply